NASDAQ · ZYNE
Zynerba Pharmaceuticals, Inc.
$1.30+$0.03 (+2.36%)
Zynerba Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.14% below the high.
Loading market information…
NASDAQ · AKYA · USD
Stock price, earnings
Quote as of Jul 8, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Akoya Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Akoya Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Akoya Biosciences, Inc. is a prominent life sciences technology firm dedicated to furnishing advanced spatial biology solutions. The company's mission is to significantly advance both discovery and clinical research across numerous global regions, including North America, Asia Pacific, Europe, the Middle East, and Africa. Their core product lineup features the PhenoCycler instrument, a compact benchtop fluidics system designed to integrate seamlessly with a microscope for automated image acquisition. Complementing this is the PhenoImager platform, which empowers researchers to intricately visualize, analyze, quantify, and characterize cells directly within diverse tissue samples—such as fresh frozen or FFPE sections and tissue microarrays—through an efficient, automated, and high-throughput process. Akoya also supplies the essential reagents for these PhenoCycler and PhenoImager systems, alongside providing specialized biopharmaceutical services. Beyond hardware, Akoya offers a robust suite of software tools. Proxima serves as a cloud-based platform for the secure storage, comprehensive analysis, and collaborative sharing of spatial data. For image interpretation, the inForm Tissue software delivers automated analysis to precisely visualize and quantify biomarkers within tissue sections. Further streamlining data workflows, Phenoptr facilitates the consolidation and in-depth analysis of output tables generated by inForm. Finally, phenoptrReports is a user-friendly software application that generates intuitive reports and visualizations from phenoptr output, presented via an easy-to-navigate graphical user interface. Established in 2015, Akoya Biosciences maintains its corporate headquarters in Marlborough, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 4, 2024 | -$0.22+18.52% vs estimate | $26.49M+2.31% vs estimate |
|---|
| Q3 2023 | Nov 8, 2023 | -$0.26+29.73% vs estimate | $25.22M-4.2% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.30+$0.03 (+2.36%)
Zynerba Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.14% below the high.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$0.76$0.00 (0.0%)
The Valens Company Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
$2.38+$0.01 (+0.42%)
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
$6.75$0.00 (0.0%)
NeueHealth, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.84% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$22.47-$0.59 (-2.56%)
Sigilon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.75% below the high.
